Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant
2007

Study on Malaria Drug Resistance in Mozambique

Sample size: 92 publication Evidence: moderate

Author Information

Author(s): Fernandes Natércia, Figueiredo Paula, do Rosário Virgilio E, Cravo Pedro

Primary Institution: Universidade Eduardo Mondlane/Faculdade de Medicina

Hypothesis

What is the prevalence of sulphadoxine/pyrimethamine resistance mutations in Plasmodium falciparum in Mozambique?

Conclusion

The high frequency of resistance mutations in P. falciparum raises concerns about the effectiveness of sulphadoxine/pyrimethamine as a first-line treatment in Mozambique.

Supporting Evidence

  • 93% of the samples had S/P resistance-associated pfdhfr triple mutants.
  • 47% of the samples had pfdhfr/pfdhps quintuple mutants.
  • No pfdhfr 164L mutants were detected in the study.

Takeaway

This study looked at how some malaria parasites in Mozambique are becoming resistant to a common treatment. They found many parasites had mutations that make the treatment less effective.

Methodology

The study screened 92 blood samples from children for resistance mutations using PCR techniques.

Limitations

The sample size may not represent the entire population of malaria parasites in Mozambique.

Participant Demographics

The participants were 92 children with uncomplicated malaria, aged between 3 months and 15 years, with a median age of 7.3 years.

Statistical Information

Confidence Interval

95% confidence interval, 0.50–5.68

Digital Object Identifier (DOI)

10.1186/1475-2875-6-35

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication